SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : PYNG Technologies -- Ignore unavailable to you. Want to Upgrade?


To: Stang who wrote (6727)5/8/2002 12:02:34 AM
From: Stang  Read Replies (1) | Respond to of 8117
 
Pyng closes 782,887-unit private placement

Pyng Technologies Corp PYT

Shares issued 10,535,478 May 6 2002 close $.450
Tuesday May 7 2002 News Release

Mr. Michael Jacobs reports

NEWS RELEASE
Pyng Technologies has closed its private placement as announced in Stockwatch April 24, 2002. Seven hundred eighty-two thousand eight hundred eighty-seven units at a price of 45 cents per unit were subscribed for together with a subscription for 65,718 common shares. Each unit comprises one common share in the capital of the company and one non-transferable common share purchase warrant. One common share purchase warrant is exercisable to purchase an additional share at a price of 55 cents for a two-year period from the date of issuance. The common shares issued under the private placement have a hold period expiring Sept. 2, 2002.
The net proceeds from the placement will be used as follows:
hire a marketing/sales director and a training co-ordinator;
continue a comprehensive marketing and sales strategy in North America;
initiate co-operative studies on the F.A.S.T.1( System in key target market EMS services throughout North America;
provide direct sales and technical assistance to distributor sales personnel and the EMS industry at large;
enhance the manufacturing processes, purchase specialized tooling for the manufacture of the component parts of the F.A.S.T.1( System;
complete all regulatory approval processes in the next targeted markets, Europe, Asia, Australasia and other areas;
expand market opportunities for the F.A.S.T.1( Intraosseous infusion technology by completing the development of derivative products; and
general corporation purposes.
In connection with the placement a cash commission of $8,496 (8 per cent of $106,200) has been paid to Raymond James Ltd.

(c) Copyright 2002 Canjex Publishing Ltd. canada-stockwatch.com

quote.stockwatch.com

Stang